Keros Therapeutics (KROS) Enterprise Value (2019 - 2025)
Keros Therapeutics' Enterprise Value history spans 7 years, with the latest figure at -$287.4 million for Q4 2025.
- For Q4 2025, Enterprise Value rose 48.67% year-over-year to -$287.4 million; the TTM value through Dec 2025 reached -$287.4 million, up 48.67%, while the annual FY2025 figure was -$287.4 million, 48.67% up from the prior year.
- Enterprise Value reached -$287.4 million in Q4 2025 per KROS's latest filing, up from -$693.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$215.6 million in Q2 2022 to a low of -$720.5 million in Q1 2025.
- Average Enterprise Value over 5 years is -$376.5 million, with a median of -$305.0 million recorded in 2023.
- Peak YoY movement for Enterprise Value: crashed 368.11% in 2021, then skyrocketed 48.67% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$230.0 million in 2021, then dropped by 21.3% to -$279.0 million in 2022, then fell by 18.67% to -$331.1 million in 2023, then crashed by 69.09% to -$559.9 million in 2024, then surged by 48.67% to -$287.4 million in 2025.
- Per Business Quant, the three most recent readings for KROS's Enterprise Value are -$287.4 million (Q4 2025), -$693.5 million (Q3 2025), and -$690.2 million (Q2 2025).